Novartis Japan Girds For Imminent Business Suspension
This article was originally published in PharmAsia News
Novartis's Japanese subsidiary must suspend the bulk of its business activities for 15 days this month following the confirmation of an expected official order in relation to the firm's tardy reporting of side-effects.
You may also be interested in...
While disappointing result will probably put an end to single-drug plans in ovarian cancer, the blockbuster anti-PD-1 immunotherapy remains in combination development for the indication.
Japanese firm in discussions with regulator as high-need novel therapy for spinocerebellar degeneration misses endpoint but shows promise in pooled analysis.